[HTML][HTML] Vismodegib exerts targeted efficacy against recurrent sonic hedgehog–subgroup medulloblastoma: results from phase II pediatric brain tumor consortium …
Journal of Clinical Oncology, 2015•ncbi.nlm.nih.gov
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup
Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B
and PBTC-032 - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive
Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC4534527 Other
Formats PDF (2.0M) Actions Cite Collections Share Permalink Copy RESOURCES Similar …
Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B
and PBTC-032 - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI
Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive
Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC4534527 Other
Formats PDF (2.0M) Actions Cite Collections Share Permalink Copy RESOURCES Similar …
Abstract
Purpose
Two phase II studies assessed the efficacy of vismodegib, a sonic hedgehog (SHH) pathway inhibitor that binds smoothened (SMO), in pediatric and adult recurrent medulloblastoma (MB).
ncbi.nlm.nih.gov